# Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

> **NCT02792218** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 930 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab subcutaneous injection
- **DRUG:** Teriflunomide-matching placebo capsules
- **DRUG:** Teriflunomide capsule
- **DRUG:** Matching placebo of ofatumumab subcutaneous injections

## Key facts

- **NCT ID:** NCT02792218
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2019-07-05
- **Final completion:** 2020-07-20
- **Target enrollment:** 930 (ACTUAL)
- **Last updated:** 2021-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02792218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02792218, "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02792218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*